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Proline-directed protein kinase FA (PDPK FA) was originally identi-
fied as type-1 protein phosphatase activating factor/glycogen
synthase kinase-3a (Vandenheede et al, 1980; Hemmings et al,
1981; Woodgett, 1990), but has subsequently been demonstrated as
a multisubstrate PDPK possibly involved in the regulation of
diverse cell functions (for reviews, see Plyte et al, 1992; Yang,
1994). Initial clinical studies revealed that PDPK FA was over-
expressed many-fold in various human cancerous tissues relative to
normal controls and the expression of PDPK FA activity appeared
to be significantly correlated with the progression states of various
human cancers (Lee et al, 1995; Yang et al, 1995, 1996, 1998). This
provided an initial evidence that overexpression of PDPK FA may
be involved in tumour promotion and progression. However, the
exact functional role of overexpressed PDPK FA in cancer has not
yet been directly demonstrated and remains to be established.
In this report, we use a more direct approach to investigate the
potential role of PDPK FA in controlling the growth of K562 cells
which were developed from leukaemia cells of a chronic myeloid
leukemia blastic phase patient by Lozzio and Lozzio (1975). We
have successfully cloned a partial sequence of PDPK FA cDNA
and constructed a recombinant antisense expression vector. The
antisense expression vector could be stably transfected into K562
cells. This results in a specific suppression of PDPK FA expres-
sion, and concomitantly leads to cell growth retardation, decreased
serum independence and poor clonogenic growth in soft agar. The
results presented here demonstrate that specific antisense suppres-
sion of PDPK FA expression is sufficient to interfere with the
growth properties of K562 cells, indicating that PDPK FA is
essential for human chronic myeloid leukaemia cell growth.
Suppression of overexpressed PDPK FA may provide a useful
clinic target for therapeutic intervention aimed at inhibiting the
malignant behaviour of human chronic myeloid leukaemia.
MATERIALS AND METHODS
Materials
Human chronic myeloid leukaemia cells (K562), derived from
leukaemia cells of a chronic myeloid leukaemia blastic phase
patient, were supplied by American Type Culture Collection
(ATCC, Rockville, MD, USA). The cells within passages 10–30
were used for all the experiments in this text. [g-32P]ATP and
enhanced chemiluminescence (ECL) Western blotting detection
reagents were purchased from Amersham (Buckinghamshire,
UK). RPMI-1640, fetal bovine serum and geneticin (G418) were
from Gibco (Paisley, UK). Benzamidine, n-a-tosyl-L-lysine
chloromethyl ketone (TLCK), phenylmethylsulphonyl fluoride
(PMSF), sodium fluoride (NaF), Triton X-100, LiCl and Tween-20
were from Merck (Darmstadt, Germany). 3-(4,5-dimethylthiazal-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), sodium orthovana-
date and 3-(cyclohexylamino)-1-propane-sulphonic acid (CAPS)
were from Sigma (St Louis, MO, USA). BCA (bacteriochlorine a)
protein assay reagent was from Pierce (Rockford, IL, USA).
Protein A-Sepharose CL-4B was from Pharmacia (Uppsala,
Sweden). Polyvinylidene fluoride (PVDF) membrane
(Immobilon-P) was from Millipore (Bedford, MA, USA).
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Phospho GS-2, mouse monoclonal anti-GSK-3b and rabbit poly-
clonal anti-Erk-1/-2 antibodies were from UBI (Lake Placid, NY,
USA). Goat anti-rabbit and anti-mouse IgG antibodies conjugated
with peroxidase were from Bio-Rad (Hercules, CA, USA).
Aprotinin and DOTAP transfection kit were from Boehringer
Mannheim (Mannheim, Germany). X-ray film was from Fuji
(Tokyo, Japan).
Production of anti-PDPK FA antibody
The peptide QAPDATPTLTNSS, corresponding to the carboxyl
terminal region from amino acids 471–483 of the sequence of FA
(Woodgett, 1990) was synthesized by peptide synthesizer (model
9050, Milligen, Bedford, MA, USA). The cysteine residue was
added to the NH2 terminus in order to facilitate coupling of the
peptide to bovine serum albumin according to the procedure
described by Reichlin (1980) using glutaraldehyde as the cross-
linker. The detailed procedure for production and affinity-purifica-
tion of this antibody was as described in previous reports (Yu and
Yang, 1993, 1994; Yang et al, 1998).
Cloning of PDPK FA cDNA and construction of
recombinant antisense expression vector
A partial sequence (~1.0 kb fragment starting from 3¢ end of FA
cDNA) was cloned from human fibroblast cells by reverse tran-
scriptase polymerization chain reaction using 5¢-CGCGGCCT-
GGAAGAGGCCAG-3¢,5 ¢-ACTGGAGGTGGGGACAGGGA-3¢,
5¢-AAGCTAGCGCCTGTGCTCGGCGCCATGA-3¢ and 5¢-TTG-
AATTCGCCCTCAGGAGGAGTTAGTG-3¢, as primers (Woodgett,
1990; He et al, 1995). The cloned cDNA fragment was constructed
into pBK-CMV vector in an antisense orientation downstream of
the cytomegalovirus (CMV) promoter using EcoRI–NheI as the
ligation sites. The neomycin-resistant gene placed downstream of
the sinian virus 40 origin was used as the second open reading
frame for initial screening of the transfected clones. The developed
antisense construct named as AtFApBK-CMV was put into mass
production in Escherichia coli and plasmid was purified by alka-
line lysis method.
Cell culture and selection of stably-transfected clones
K562 cells were cultured in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 25 U ml–1 penicillin
and 25 mg ml–1 streptomycin. Cells were incubated at 37°C in a
95% air/5% carbon dioxide (CO2) and water-saturated atmosphere
in 75-cm2 flasks. For transfection, pBK-CMV vector alone as
control, or AtFApBK-CMV vector as antisense construct as
described above was introduced into cells by DOTAP. Briefly,
10 mg vector mixed with DOTAP was incubated with 1 ´ 106 cells
in serum-free medium at 37°C for 6 h. The transfected cells were
then seeded in 96-well plate (1 ´ 104 cells per well) with complete
medium containing 400 mg ml–1 geneticin (G418) for selection of
recombinant clones expressing G418 resistance. After 4 weeks,
individual clones surviving in the presence of G418 were further
expanded to mass culture.
Cell extract preparation
For cell extract preparation, 2.5 ´ 106 cells washed twice with ice-
cold phosphate-buffered saline (PBS) were suspended in 500 ml
solution A (10 mM Tris–HCl at pH 7.4, 2 mM EDTA, 1 mM EGTA,
50 mM sodium chloride (NaCl), 1% Triton X-100, 1 mM PMSF,
1m M benzamidine, 0.5 mg ml–1 aprotinin, 50 mM NaF, 20 mM
sodium pyrophosphate and 1 mM sodium orthovanadate) and then
homogenized on ice by Sonic Dismembrator (model 150, Fisher)
for 3 ´ 10 s at 40% power output. Cell lysates were then ultra-
centrifuged at 100 000 g for 30 min at 4°C and the supernatants
were used as the cell extracts. Protein concentration of the cell
extract was determined by BCA protein assay and adjusted to
1 mg ml–1 with solution A.
Immunoprecipitation and PDPK FA activity assay in the
immunoprecipitate
Cell extract (300 mg cell protein) was incubated with 0.5 ml
affinity-purified anti-PDPK FA antibody (1.5 mg pure IgG) at 4°C
for 1.5 h and then with 100 ml protein A-Sepharose CL-4B (20% 
vv in solution A) for another 1.5 h with shaking. The immunopre-
cipitate was collected by centrifugation, washed twice with solu-
tion B (20 mM Tris–HCl at pH 7.0, 0.5 mM dithiothreitol (DTT), 1
mM PMSF, 1 mM benzamidine, and 0.1 mM aprotinin) containing
0.5 M LiCl, once with 1 ml solution B, and then resuspended in
200 ml solution B. For PDPK FA activity assay in the immuno-
precipitate, 10 ml immunoprecipitate at appropriate dilution were
incubated with 15 ml mixture containing 20 mM Tris–HCl at 
pH 7.0, 0.5 mM DTT, 10 mg heparin, 0.2 mM [g-32P]ATP 
(~1000 cpm pmol–1), 20 mM magnesium chloride (MgCl2) and 60
mM phospho GS-2 (YRRAAVPPSPSLSRHSSPHQ-pSEDEEE) at
30°C for 10 min. 32P-incorporation was measured by spotting 20
ml reaction mixture on phosphocellulose paper (1 ´ 3c m 2),
washing 3 times with 75 mM phosphoric acid (H3PO4) and
counting in liquid scintillation counter. A unit of PDPK FA is that
amount of enzyme that incorporates 1 pmol of phosphate per min
into the peptide substrate.
Immunoblot analysis
For immunoblot analysis, the cell extract containing 10 mg cell
protein was subjected to 10% sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE), electrotransferred to
PVDF membrane and then immunoblotted with 50 ng ml–1
primary antibodies as indicated and then with goat anti-rabbit or
anti-mouse IgG antibody conjugated with peroxidase (1:3000)
essentially as described in previous reports (Yang et al, 1994,
1998; Yu and Yang, 1994). Immunoblot was developed with the
ECL system using peroxidase substrate at 25°C for chemilumines-
cence detection (Gillespie and Hudspeth, 1991). The luminescent
light emission was recorded on X-ray film and quantified by
computing densitometer (Molecular Dynamics, Sunnyvale, CA,
USA).
Clonogenic growth in soft agar
Antisense and control-transfected clones of K562 cells were plated
in soft agar for clonogenicity as described by Jeha et al (1996).
Briefly, a feeder layer consisting of medium supplemented with
20% serum and 0.5% agarose was plated in a 60-mm tissue culture
dish. The feeder layer was overlaid with a top layer that included
1 ´ 104 cells with 20% serum and 0.35% agarose. After 10 days,
colonies were stained with 2 ml of 1 mg ml–1 MTT solution at
37°C for 12 h and then counted and photographed.1482 C-P Hsu et al
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RESULTS
Establishment and characterization of antisense clones
that stably induced a decrease of PDPK FA
Transfection of K562 cells was performed with AtFApBK-CMV
vector as the antisense construct or with pBK-CMV vector as
control following G418 selection as described in Materials and
Methods. Several G418-resistant clones were successfully
subcloned and expression levels of PDPK FA were determined by
immunoprecipitate kinase assay for cellular activity and by
immunoblot analysis for protein expression. Similar protein and
activity levels (70 ± 5 units mg–1 cell protein) of PDPK FA were
found to exist in both untransfected parental and control-trans-
fected clones (data not further illustrated). The results indicate that
neither transfection nor G418 treatment could affect the expression
of PDPK FA in K562 cells. In contrast, two antisense clones were
obtained in which the cellular activities of PDPK FA were
decreased to the levels of 50 ± 3 units mg–1 cell protein (As1) and
30 ± 4 units mg–1 cell protein (As2) respectively (Figure 1A).
Immunoblot analysis revealed that the protein levels of PDPK FA
in these two antisense clones were also suppressed in a similar
manner (Figure 1B). Computing densitometric analysis further
revealed that the protein levels of As1 and As2 were suppressed to
70% and 45% of control level respectively (Figure 1C). The
suppressed activity (Figure 1A) and protein (Figure 1 B, C) levels
of PDPK FA in the antisense clones appeared to be very similar,
demonstrating that inhibition of PDPK FA activity in antisense
clones is due to suppression of the protein expression. Moreover,
although the DNA sequence of PDPK FA has 85% identity with
glycogen synthase kinase-3b (GSK-3b) (Woodgett, 1990), the
PDPK FA antisense expression vector constructed here appeared to
have no significant effect on the protein expression of GSK-3b in
K562 cells (not shown). We also determined another well-
established PDPK member, namely the mitogen-activated protein
kinases (MAPKs), and again no significant effect on the expres-
sion of Erk-1/-2 in these two antisense clones could be observed
(not shown). The results demonstrate that the antisense expression
vector constructed here specifically suppressed PDPK FA in K562
cells and had no effect on the expression of the other DNA
sequence-homologous PDPK members such as GSK-3b and
MAPKs.
Suppression of PDPK FA expression in antisense
clones resulted in blocking the growth of K562 cells
To study the role of PDPK FA in controlling the growth of K562
cells, the biological properties of antisense expressing K562 cells
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Figure 1 Suppression of PDPK FA protein expression in antisense clones
of K562 cells. The cell extracts (300 mg cell protein) of PDPK FA antisense
(As1 and As2) and control-transfected (control) clones as indicated were
immunoprecipitated by using 1.5 mg anti-PDPK FA antibody. The PDPK FA
activity in the immunoprecipitate was measured using phospho GS-2 as
substrate (A). The same cell extracts containing 10 mg cell protein were
subjected to 10% SDS-PAGE, electrotransfered to PVDF membrane and
immunoblotted with 50 ng ml–1 of anti-PDPK FA antibody (B) followed by
computing densitometric quantification of the relative amount of PDPK FA (%
of control) on the immunoblot (C). Data were taken from the representative
results of three independent experiments and expressed as means ± s.d.
As1/As2: the two antisense clones of K562 cells stably transfected with
PDPK FA antisense expression vector
Table 1 Biological properties of PDPK FA antisense clones of K562 cells
Cell clonesa Protein level of Doubling timec Soft agar coloniesd
PDPK FA
b
(% of control) (H) (% Colonies/dish)
Control 100 18.2 ± 0.6 100
As1 70 20.1 ± 0.4 12.2 ± 0.5
As2 45 24.3 ± 0.3 2.4 ± 0.8
aControl, control-transfected clone; As1/As2, the two PDPK FA antisense
clones. bThe relative amount of PDPK FA determined by immunoblot
analysis. cAntisense or control clones (2.5 ´ 104 cells ml–1) were cultured at
37°C in medium supplemented with 10% serum and counted every 24 h by
trypan blue exclusion method. The doubling time was calculated during the
exponential growth phase. Results are the averages of four independent
experiments and expressed as means ± s.d. dAntisense or control clones 
(1 ´ 104 cells/dish) in a top layer consisting of medium supplemented with
20% serum and 0.35% agarose were overlaid on the feeder layer consisting
of medium supplemented with 20% serum and 0.5% agarose in 60-mm
culture dish. After 10 days at 37°C, colonies were stained with 2 ml mg–1 ml–1
MTT solution at 37°C for 12 h. Data were taken from the averages of three
independent experiments and expressed as % of control.PDPK FA in leukaemia cell growth 1483
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were examined. In studying the growth property of the antisense
clones, we found that the two antisense clones proportionally had
lower growth rates compared with control-transfected cells.
Doubling time, calculated during the exponential growth phase,
was significantly and proportionally increased from 18.2 h of
control up to 24.3 h as summarized in Table 1. Since clonogenic
growth in soft agar was established as an important parameter that
has the best correlation with in vivo tumorigenicity (Freedman and
Shin, 1974; Shin et al, 1975; Jeha et al, 1996), we next subjected
all the cell clones to the analysis of clonogenic growth in soft agar.
The most inhibited antisense clone (As2) had almost no ability of
forming colonies in soft agar and intermediate phenotype was
observed in the clone expressing intermediate level of PDPK FA
(As1) as shown in Figure 2 and summarized in Table 1. The results
demonstrate that specific suppression of PDPK FA expression is
sufficient to inhibit proliferation and to diminish clonogenic
potential of K562 cells in soft agar. Moreover, since non-trans-
formed cells have a greater degree of dependence on serum for
their growth than their transformed counterparts (Holley and
Kiernan, 1968; Todaro and DeLarco, 1978; Jeha et al, 1996), we
also determined the serum-dependent growth change in the anti-
sense clones. K562 cells like most transformed cells, were able to
grow well even in 0.5% serum (Figure 3). In sharp contrast, the
antisense clone with low level of PDPK FA could not grow at all in
0.5% serum (Figure 3). Therefore, by reducing expression of
PDPK FA in the antisense-transfected cells, a more normal pheno-
type, that of serum-dependent growth was restored. All the results
taken together demonstrate that specific suppression of PDPK FA
expression is sufficient to interfere with the growth properties of
K562 cells.
DISCUSSION
In this study, cloning of PDPK FA cDNA and its antisense expres-
sion vector and specific antibody were successfully established.
The antisense expression vector could be stably introduced into
human chronic myeloid leukaemia cells K562. Two stable anti-
sense clones were subcloned, which constitutively suppressed
~30% and ~55% of the total PDPK FA activity in the untransfected
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Figure 3 Serum-dependent growth in PDPK FA antisense clone. PDPK FA
antisense (As2) and control-transfected (control) clones (2.5 ´ 105 cells) were
cultured in different concentrations of serum as indicated at 37°C for four
days and the viable cells were counted by trypan blue exclusion method.
Results are the averages of four independent experiments and expressed as
means ± s.d
Figure 2 Assessment of clonogenicity of PDPK FA antisense clones in soft
agar. Clonogenicity of PDPK FA antisense (As1 and As2) and control-
transfected (control) clones was assessed by growing 1 ´ 104 cells in 0.35%
agarose to form colonies as described in Materials and Methods. After 10
days, the colonies stained with MTT solution at 37°C for 12 h were
photographed. Data were taken from the representative results of three
independent experiments1484 C-P Hsu et al
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parental cells respectively. Data presented here first demonstrate
that endogenous PDPK FA expression in leukaemia cells can be
suppressed by genetic engineering. Although the DNA sequence
homology between PDPK FA and GSK-3b is ~85% (Woodgett,
1990), the constructed antisense vector presented here displayed
little effect on the expression of GSK-3b in K562 cells. We also
tested the effect of this PDPK FA-specific antisense vector on the
well-established PDPK member, namely Erk-1/-2, and again no
suppression of Erk-1/-2 expression could be observed. The results
taken together demonstrate that the antisense expression vector
constructed here can potently and specifically suppress the
endogenous PDPK FA expression in K562 cells.
By using the PDPK FA-specific antisense expression vector
developed in the present study, we further demonstrate that
specific suppression of PDPK FA expression in the stable trans-
fected antisense clones proportionally and potentially leads to a
modification of the leukaemia malignant phenotypes. These
included prolonged doubling time, poor clonogenic growth in soft
agar and increased serum dependence. The decreased serum
requirement of transformed cells has been attributed to autocrine
growth stimulation by growth factor-like molecules that are
produced by the cancer cells themselves (Holley and Kiernan,
1968; Todaro and DeLarco, 1978; Jeha et al, 1996). The increased
serum requirement of antisense clones presented here provides
evidence that PDPK FA may play an important role in autocrine
growth stimulation process of chronic myeloid leukaemia.
Moreover, since clonogenic growth in soft agar was established to
have the best correlation with in vivo tumorigenicity (Freedman
and Shin, 1974; Shin et al, 1975; Jeha et al, 1996), the diminished
clonogenicity in antisense clones presented here strongly impli-
cates that PDPK FA may play an essential role in regulating human
chronic myeloid leukaemia cell growth. PDPK FA may, therefore,
represent a potential new target for anticancer research. Whether
suppression of PDPK FA activity using PDPK FA blockers such as
genistein, kaempferol, apigenin and quercetin (Yang et al, 1998;
Lee et al, 1998) may provide a useful clinic target for therapeutic
intervention inhibiting the malignant behaviour of chronic
myeloid leukaemia obviously presents an intriguing issue
deserving further investigation. Nevertheless, the present study
clearly demonstrates that specific suppression of proline-
directed directed protein kinase FA is sufficient to interfere with the
growth of human chronic myeloid leukaemia cells, providing an
initial evidence for a critical role of this PDPK in leukaemia cell
growth.
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